

CLINICAL STUDY

Efficacy and safety of Aloe vera syrup for the treatment of gastroesophageal reflux disease: a pilot randomized positive-controlled trial

Yunes Panahi, Hossein Khedmat, Ghasem Valizadegan, Reza Mohtashami, Amirhossein Sahebkar

Yunes Panahi, Chemical Injuries Research Center, Baqiyatallah University of Medical Sciences, Tehran 19945581, Iran

Hossein Khedmat, Baqiyatallah Research Center for Gastroenterology and Liver Diseases, Baqiyatallah University of Medical Sciences, Tehran 19945581, Iran

Ghasem Valizadegan, Baqiyatallah University of Medical Sciences, Tehran 19945581, Iran

Reza Mohtashami, Medicine, Quran and Hadith Research Center, Baqiyatallah University of Medical Sciences, Tehran 19945581, Iran

Amirhossein Sahebkar, Biotechnology Research Center, Mashhad University of Medical Sciences, Mashhad 9177948564, Iran; Metabolic Research Centre, Royal Perth Hospital, School of Medicine and Pharmacology, University of Western Australia, Perth X2213, Australia

Supported by the Clinical Trial Research Center, Tehran, Iran
Correspondence to: Amirhossein Sahebkar, Department of Medical Biotechnology, School of Medicine, Mashhad University of Medical Sciences, Mashhad 9177948564, Iran. sahebkar@mums.ac.ir

Telephone: +98-5138002288

Accepted: September 21, 2014

main symptoms of GERD (heartburn, food regurgitation, flatulence, belching, dysphagia, nausea, vomiting and acid regurgitation) were assessed at weeks 2 and 4 of the trial.

RESULTS: A. vera was safe and well tolerated and reduced the frequencies of all the assessed GERD symptoms, with no adverse events requiring withdrawal.

CONCLUSION: A. vera may provide a safe and effective treatment for reducing the symptoms of GERD.

© 2015 JTCM. All rights reserved.

Key words: Aloe vera; Gastroesophageal reflux disease; Complementary therapies; Treatment outcome; Randomized controlled trial

Abstract

OBJECTIVE: To investigate the use of Aloe vera (A. vera) for the treatment of gastroesophageal reflux disease (GERD) symptoms and compare its effects with those of omeprazole and ranitidine.

METHODS: In this pilot, randomized controlled trial, 79 subjects were allocated to A. vera syrup (standardized to 5.0 mg polysaccharide per mL of syrup) at a dose of 10 mL/d, omeprazole capsule (20 g/d) or ranitidine tablet (150 mg in a fasted state in the morning and 150 mg 30 min before sleep at night) for a period of 4 weeks. The frequencies of eight

INTRODUCTION

Gastroesophageal reflux disease (GERD) is a chronic, recurrent and progressive disease associated with a wide range of esophageal (e.g. esophageal ulcer, esophageal cancer, Barrett's disease) as well as non-esophageal (e.g. respiratory problems, chest pain, angina) complications. Mucosal damage caused by gastric refluxate means that GERD occasionally shows similar symptoms to functional dyspepsia and irritable bowel syndrome.¹

Official statistics suggest that 44% of the population of the United States experience GERD symptoms at least once a month, and 20% at least once a week.^{2,3} The overall prevalence of GERD in the Western world has been reported to be about 10%-20%, making it one of the most common gastrointestinal diseases.⁴ However,

despite the high prevalence of GERD, its definitive diagnosis and clinical differentiation from other morbidities is difficult, at least partly because of the presence of atypical manifestations such as laryngopharyngeal reflux, chronic cough, asthma and dental erosions.¹ Notably, GERD symptoms have been reported to adversely affect patients' daily activities and quality of life, and impose a substantial cost on healthcare systems.^{5,6}

Regarding the recurrent nature of GERD, most patients require continuous and long-term medication. Proton pump inhibitors and H₂ receptor blockers are the most commonly prescribed drug classes for GERD. However, despite their proven effect and widespread use, adverse events such as hypochlorhydria, cardiac events and increased risk of hip fractures have led to concerns over the safety of these drugs,^{7,8} resulting in a surge of interest in identifying natural remedies that can effectively control GERD symptoms and prevent its complications.

Aloe vera (*A. vera*) is a medicinal plant with wide applications in the pharmaceutical industry for both systemic^{9,10} and dermatologic disorders.¹¹⁻¹⁴ *A. vera* gel has been demonstrated to possess several pharmacological actions including antioxidant, anti-inflammatory, analgesic, anti-proliferative, and anti-diabetic properties.¹⁵ Furthermore, *A. vera* has also shown anti-ulcer,^{16,17} wound-healing,¹⁸ and antimicrobial¹⁹ effects, all of which may be relevant to the treatment of GERD and its comorbidities. However, despite these promising mechanisms of action and positive findings in preclinical models of GERD and peptic ulcers,^{16,17} clinical evaluations of *A. vera* gel as a treatment for GERD have been scarce. The present trial aimed to explore the clinical efficacy of *A. vera* syrup compared with the standard medications omeprazole and ranitidine in patients suffering from GERD symptoms.

METHODS

Subjects

This randomized, open-label, positive-controlled clinical trial enrolled patients aged 18-65 years who were diagnosed with GERD and referred to the endoscopy ward at the Baqiyatallah Hospital (Tehran, Iran). The study protocol was approved by the institutional Ethics Committee and written informed consent was obtained from all participants. Exclusion criteria were pregnancy, breastfeeding, and presence of hematemesis, odynophagia, treatment-resistant GERD, other gastrointestinal disorders (e.g. peptic ulcer, irritable bowel syndrome, obstructive diseases), hepatic diseases, malnutrition syndrome, hematologic diseases, use of muscle relaxant drugs (e.g. anticholinergic agents, calcium channel blockers), or history of hypersensitivity to *A. vera* preparations.

Treatments

Seventy-nine eligible subjects were randomly allocated

to *A. vera* syrup (10 mL once a day), omeprazole capsule (20 mg once a day) or ranitidine tablet (150 mg in a fasted state in the morning and 150 mg 30 min before sleep at night) for a period of 4 weeks. Randomization was performed using a random-number table controlled by the pharmacy. *A. vera* syrup was formulated by the Barij Essence Pharmaceutical Co., (Mashade Ardehal, Kashan, Iran), and was standardized to 5.0 mg polysaccharide per mL of syrup.

Efficacy measures

Assessment of treatment efficacy was symptom-based.^{20,21} Improvements in common GERD symptoms were measured according to a modified Reflux Disease Questionnaire,²² which is a validated, self-administered scale that is widely used for the assessment of anti-reflux treatment effects.²³ The frequencies of eight main symptoms of GERD, namely heartburn, food regurgitation, flatulence, belching, dysphagia, nausea, vomiting and acid regurgitation, were assessed at weeks 2 and 4 of the trial and were compared between the different treatment arms.

Statistical analysis

Statistical analyses were performed using SPSS software version 16.0 (SPSS Inc., Chicago, IL, USA). Within-group comparisons of the frequencies of GERD symptoms were carried out using the binomial sign test. Between-group comparisons were made using Pearson's χ^2 or Fisher's exact test. Quantitative data are expressed as the mean \pm standard deviation ($\bar{x} \pm s$). In all analyses, a two-sided *P* value < 0.05 was considered to be statistically significant.

RESULTS

The demographic characteristics of the study groups including age, sex, body mass index, educational level and smoking habit are shown in Table 1. There were no significant differences in any of these parameters between the groups.

The severities of GERD symptoms were assessed after 2 and 4 weeks of treatment. The baseline frequencies of all the evaluated GERD symptoms were similar in the *A. vera*, ranitidine and omeprazole groups (*P* > 0.05). The frequencies of all GERD symptoms were reduced at both 2 and 4 weeks of treatment in the *A. vera* group compared with baseline, with a trend towards further improvement in the frequencies of heartburn, flatulence and belching from weeks 2-4 of the trial (Table 2).

In the omeprazole group, the frequencies of all assessed symptoms were significantly reduced compared with baseline at both time points (weeks 2 and 4) and the frequencies of heartburn, flatulence, belching and acid regurgitation showed further reductions at week 4 compared with week 2 (Table 2).

In the ranitidine group, the frequencies of heartburn,

flatulence, belching, nausea, vomiting and acid regurgitation were significantly reduced at week 2 compared with baseline. The frequencies of all assessed symptoms except flatulence were significantly reduced at week 4 compared with both baseline and week 2, while flatulence was reduced at week 4 compared with week 2 (Table 2).

A. vera had less effect on reducing the frequencies of heartburn at weeks 2 and 4 compared with omeprazole, and at week 4 compared with ranitidine, and less effect on flatulence at week 4 compared with omeprazole, and at weeks 2 and 4 compared with ranitidine. Patients in the A. vera group also had a higher frequency of belching at week 4 compared with patients in the omeprazole group. Frequencies of other symptoms were comparable between the study groups.

There were two reports of adverse reactions in the A. vera group (one vertigo and one stomachache), three in the omeprazole group (one headache, one constipation

and one heartburn), and three in the ranitidine group (one of constipation, two heartburn, and two diarrhea) (Table 3). These adverse events were responsible for two drop-outs in the ranitidine group and two in the omeprazole group, but none in the A. vera group.

DISCUSSION

The results of the present randomized controlled trial provide evidence for the efficacy of A. vera gel syrup in reducing the common symptoms of GERD. This efficacy of A. vera was comparable to those of the standard drugs ranitidine and omeprazole in relation to most symptoms. An epidemiological study in Poland reported that A. vera was routinely used to treat gastric hyperacidity, as well as gastric and duodenal ulcers in cigarette smokers.²⁴ In an experimental study, intravenous administration of aloctin A, a glycoprotein present in Aloe species, was shown to reduce the secretion of gas-

Table 1 Demographic characteristics of study subjects ($\bar{x} \pm s$)

Parameter		Aloe vera	Omeprazole	Ranitidine
N		28	27	24
Female (n)		15	19	11
Age (years)		46±17	48±17	47±14
BMI (kg/m ²)		52±4	26±5	25±4
Smoking (n)		3	3	2
Educational level (n)	Illiterate	3	3	3
	Under diploma	11	11	11
	Diploma	4	8	4
	University	10	5	15

Note: BMI: body mass index.

Table 2 Frequency of GERD symptoms in the study groups at baseline, and at weeks 2 and 4 of the trial [n (%)]

Item	Aloe vera			Omeprazole			Ranitidine		
	Baseline	Week 2	Week 4	Baseline	Week 2	Week 4	Baseline	Week 2	Week 4
Heartburn	17 (100.0)	4 ^a (23.5)	5 ^a (29.4)	24 (100.0)	13 ^{ab} (54.2)	15 ^{ab} (62.5)	25 (100.0)	9 ^a (36.0)	13 ^{ab} (52.0)
Food regurgitation	10 (100.0)	1 ^a (10.0)	1 ^a (10.0)	11 (100.0)	2 ^a (18.2)	2 ^a (18.2)	16 (100.0)	1 (6.3)	2 ^a (12.5)
Dysphagia	12 (100.0)	4 ^a (33.3)	4 ^a (33.3)	12 (100.0)	1 ^a (8.3)	1 ^a (8.3)	9 (100.0)	0 (0.0)	2 (12.5)
Flatulence	17 (100.0)	1 ^a (5.9)	2 ^a (11.8)	21 (100.0)	5 ^a (23.8)	9 ^{ac} (42.9)	23 (100.0)	12 ^{ac} (52.1)	7 ^{ac} (30.4)
Belching	15 (100.0)	2 ^a (13.3)	3 ^a (20.0)	19 (100.0)	7 ^a (36.8)	10 ^{ab} (52.6)	21 (100.0)	3 ^a (14.3)	7 ^a (30.4)
Nausea	5 (100.0)	1 ^a (20.0)	1 ^a (20.0)	12 (100.0)	4 ^a (33.3)	4 ^a (33.3)	15 (100.0)	8 ^a (53.3)	10 ^a (66.7)
Vomiting	1 (100.0)	1 (100.0)	1 (100.0)	3 (100.0)	2 ^a (66.7)	2 ^a (66.7)	6 (100.0)	2 ^a (33.3)	4 ^a (66.7)
Acid regurgitation	20 (100.0)	10 ^a (50.0)	10 ^a (50.0)	20 (100.0)	12 ^a (60.0)	13 ^a (65.0)	24 (100.0)	10 ^a (41.7)	16 ^a (66.7)

Notes: GERD: gastroesophageal reflux disease. ^a $P < 0.05$: within group comparison with respect to baseline value; ^bborderline significant difference versus A. vera group at the respective time point; ^cbetween-group comparison at respective time point (week 2 or 4) in the A. vera group.

Table 3 Reported adverse events in the study groups [n (%)]

Item	Aloe vera	Omeprazole	Ranitidine
Headache	0 (0.0)	1 (4.0)	0 (0.0)
Constipation	0 (0.0)	1 (4.0)	1 (4.5)
Heartburn	0 (0.0)	1 (4.0)	2 (9.1)
Vertigo	1 (3.8)	0 (0.0)	0 (0.0)
Diarrhea	0 (0.0)	0 (0.0)	2 (9.1)
Stomachache	1 (3.8)	0 (0.0)	0 (0.0)
Tenesmus	0 (0.0)	0 (0.0)	0 (0.0)
None	24 (92.3)	23 (88.0)	19 (86.4)

tric juice, acid and pepsin, and inhibit acute gastric lesions in rats.²⁵ Another study in rats with gastric ulcers showed that treatment with *A. vera* reduced leukocyte adherence to postcapillary venules, elevated serum concentrations of interleukin-10, and reduced serum tumor necrosis factor- α (TNF- α). In addition, histopathological examination revealed reduced gastric inflammation and ulcer size, and enhanced epithelial cell proliferation and gastric gland growth following *A. vera* treatment. These protective effects of *A. vera* were comparable to those of the standard drug sucralfate.¹⁷

Oxidative stress and inflammation have been implicated as key factors in the pathophysiology of GERD.²⁶ The efficacy of *A. vera* gel in reducing the symptoms of GERD might thus be partly attributable to its antioxidant and anti-inflammatory ingredients.²⁷ *A. vera* possesses antioxidant capacity and was shown to reduce oxidative damage in several experimental models, including CCL₄-induced hepatotoxicity and chronic liver fibrosis.²⁸ There are several mechanisms responsible for the antioxidant actions of *A. vera*, including scavenging of free radicals, reduction of lipid peroxidation and up-regulation of antioxidant enzymes.^{27,29,30} In addition, leukocyte infiltration and circulating concentrations of TNF- α were significantly reduced following administration of *A. vera* to *Helicobacter pylori*-infected mice.³¹ Of relevance to its role in gastrointestinal disorders, *A. vera* has shown strong antimicrobial effects against *H. pylori*,¹⁹ as well as having a reducing effect on gastric acid secretion.³² This effect has been proposed to be associated with the action of lectins present in *A. vera*, which inhibit aminopyrin uptake by parietal cells, thereby reducing acid secretion.³³

The results of the present study indicated that consumption of *A. vera* was safe and well tolerated, and unlike the comparator treatments, its use was not associated with treatment withdrawal. This plant has been classified as Generally Recognized As Safe based on clinical evidence and a long ethnobotanical history supporting its safety. Furthermore, *A. vera* preparations are relatively inexpensive and widely available, and have been shown to possess therapeutic activities against several other disorders that commonly accompany GERD, such as peptic ulcers,^{16,17} irritable bowel syn-

drome,³⁴ ulcerative colitis,³⁵ type 2 diabetes^{9,10} and dyslipidemia.^{9,10}

To conclude, the results of this pilot, randomized controlled trial indicate that *A. vera* syrup provides a safe and effective treatment for reducing the frequency of GERD symptoms. *A. vera* should therefore be suggested as an effective supplement in patients suffering from GERD. Further studies are needed to investigate the impact of treatment with higher doses of *A. vera*, and also to explore the efficacy of *A. vera* treatment in reducing long-term complications of GERD such as Barrett's esophagus, esophageal strictures, erosive esophagitis and esophageal carcinoma.

REFERENCES

- 1 **Lee SY**, Lee KJ, Kim SJ, Cho SW. Prevalence and risk factors for overlaps between gastroesophageal reflux disease, dyspepsia, and irritable bowel syndrome: a population-based study. *Digestion* 2009; 79(3): 196-201.
- 2 **Petersen H**. The prevalence of gastroesophageal reflux disease. *Scan J Gastroenterol Suppl* 1995; 211: 5-6.
- 3 **Locke GR 3rd**, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ 3rd. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. *Gastroenterology* 1997; 112(5): 1448-1456.
- 4 **Dent J**, El-Serag HB, Wallander M-A, Johansson S. Epidemiology of gastroesophageal reflux disease: a systematic review. *Gut* 2005; 54(5): 710-717.
- 5 **McDougall NI**, Johnston BT, Kee F, et al. Natural history of reflux oesophagitis: a 10 year follow up of its effect on patient's symptomatology and quality of life. *Gut* 1996; 38: 481-486.
- 6 **Farup C**, Kleinman L, Sloan S, et al. The impact of nocturnal symptoms associated with gastroesophageal reflux disease on health-related quality of life. *Arch Intern Med* 2001; 161(1): 45-52.
- 7 **Yang YX**, Lewis JD, Epstein S, Metz DC. Long-term proton pump inhibitor therapy and risk of hip fracture. *JA-MA* 2006; 296(24): 2947-2953.
- 8 **Ament PW**, Dicola DB, James ME. Reducing adverse effects of proton pump inhibitors. *Am Fam Physician* 2012; 86(1): 66-70.
- 9 **Ngo MQ**, Nguyen NN, Shah SA. Oral aloe vera for treat-

- ment of diabetes mellitus and dyslipidemia. *Am J Health Syst Pharm* 2010; 67(21): 1804-1811.
- 10 **Huseini HF**, Kianbakht S, Hajiaghache R, Dabaghian FH. Anti-hyperglycemic and anti-hypercholesterolemic effects of aloe vera leaf gel in hyperlipidemic type 2 diabetic patients: a randomized double-blind placebo-controlled clinical trial. *Planta Med* 2012; 78(4): 311-316.
 - 11 **Feily A**, Namazi MR. Aloe vera in dermatology: a brief review. *G Ital Dermatol Venereol* 2009; 144(1): 85-91.
 - 12 **Panahi Y**, Davoudi SM, Sahebkar A, et al. Efficacy of Aloe vera/olive oil cream versus betamethasone cream for chronic skin lesions following sulfur mustard exposure: a randomized double-blind clinical trial. *Cutan Ocul Toxicol* 2012; 31(2): 95-103.
 - 13 **Panahi Y**, Sharif MR, Sharif A, et al. A randomized comparative trial on the therapeutic efficacy of topical aloe vera and calendula officinalis on diaper dermatitis in children. *Scientific World Journal* 2012; 2012: 810234.
 - 14 **Panahi Y**, Beiraghdar F, Akbari H, Bekhradi H, Taghizadeh M, Sahebkar A. A herbal cream consisting of Aloe vera, Lavandulastoechas, and Pelargonium roseum as an alternative for silver sulfadiazine in burn management. *Asian Biomed* 2012; 6(2): 273-278.
 - 15 **Surjushe A**, Vasani R, Saple D. Aloe vera: a short review. *Indian J Dermatol* 2008; 53(4): 163-166.
 - 16 **Akpan UP**, Nna VU, Ekpenyong CE, Antai AB, Osim EE. Protective role of crude Aloe vera gel against gastric ulcers in alloxan - Induced diabetic rats. *Res J Pharm Biol Chem Sci* 2014; 5(2): 129-138.
 - 17 **Eamlamnam K**, Patumraj S, Visedopas N, Thong-Ngam D. Effects of aloe vera and sucralfate on gastric microcirculatory changes, cytokine levels and gastric ulcer healing in rats. *World J Gastroenterol* 2006; 12(13): 2034-2039.
 - 18 **Wang XT**, Teng YJ, Ge XJ, et al. Effectiveness of aloe vera for acute and chronic wounds: a systematic review. *Chin J Evid Based Med* 2013; 13(4): 468-473.
 - 19 **Santhosh Kumari CH**, Prasad CVN, Sree Ramulu J. Determination of in-vitro and in-vivo activities of aloe vera. L Against H. Pylori. *Int J Pharma Bio Sci* 2010; 1(2): 124.
 - 20 **Fraser A**, Delaney B, Moayyedi P. Symptom-based outcome measures for dyspepsia and GERD trials: a systematic review. *Am J Gastroenterol* 2005; 100(2): 442-452.
 - 21 **Mouli VP**, Ahuja V. Questionnaire based gastroesophageal reflux disease (GERD) assessment scales. *Indian J Gastroenterol* 2011; 30(3): 108-117.
 - 22 **Shaw MJ**, Talley NJ, Beebe TJ, et al. Initial validation of a diagnostic questionnaire for gastroesophageal reflux disease. *Am J Gastroenterol* 2001; 96(1): 52-57.
 - 23 **Thomas E**, Wade A, Crawford G, Jenner B, Levinson N, Wilkinson J. Randomised clinical trial: relief of upper gastrointestinal symptoms by an acid pocket-targeting alginate-antacid (Gaviscon Double Action) - a double-blind, placebo-controlled, pilot study in gastro-oesophageal reflux disease. *Aliment Pharmacol Ther* 2014; 39(6): 595-602.
 - 24 **Gawron- Gzella A**, htkowska-Banaszczak E. Herbs and herbal preparations applied in the treatment of gastric hyperacidity, gastric and duodenal ulcer in cigarette smokers. *Przegl Lek* 2005; 62(10): 1185-7.
 - 25 **Saito H**, Imanishi k. Effects of Aleo extracts, Aloction A on gastric secretion and on experimental gastric lesions in rats. *Yakugaku Zashi* 1989; 109(5): 335-339.
 - 26 **Yoshida N**. Inflammation and oxidative stress in gastroesophageal reflux disease. *J Clin Biochem Nutr* 2007; 40(1): 13-23.
 - 27 **Kaithwas G**, Singh P, Bhatia D. Evaluation of *in vitro* and *in vivo* antioxidant potential of polysaccharides from Aloe vera (Aloe barbadensis Miller) gel. *Drug Chem Toxicol* 2014; 37(2): 135-143.
 - 28 **Nahar T**, Uddin B, Hossain S, Sikder AM, Ahmed S. Aloe vera gel protects liver from oxidative stress-induced damage in experimental rat model. *J Complement Integr Med* 2013; 10.
 - 29 **Mohapatra S**, Pradhan S, Rath B, Tripathy S. Antioxidant properties of aloe vera in streptozotocin induced diabetic rats. *Int J Pharma Bio Sci* 2013; 4(3): P187-P191.
 - 30 **Haritha K**, Ramesh B, Saralakumari D. Effect of Aloe vera gel on antioxidant enzymes in streptozotocin-induced cataractogenesis in male and female Wistar rats. *J Acute Med* 2014; 4(1): 38-44.
 - 31 **Duansak D**, Somboonwong J, Patumraj S. Effects of Aloe vera on leukocyte adhesion and TNF- α and IL-6 levels in burn wounded rats. *Clin Hemorheol Microcirc* 2003; 29(3-4): 239-246.
 - 32 **Keshavarzi Z**, Rezapour TM, Vatanchian M, Zare Hesari M, Nabizade Haghghi H, Izanlu M, et al. The effects of aqueous extract of Aloe vera leaves on the gastric acid secretion and brain and intestinal water content following acetic acid-induced gastric ulcer in male rats. *Avicenna J Phytomed* 2014; 4(2): 137-143.
 - 33 **Blitz J**, Smith J, Gerard J. Aloe Vera Gel in peptic ulcer therapy; Preliminary report. *J American Osteopathic Assoc* 1963; 62: 731-735.
 - 34 **Asadi-Shahmirzadi A**, Mozaffari S, Sanei Y, et al. Benefit of Aloe vera and Matricaria recutita mixture in rat irritable bowel syndrome: Combination of antioxidant and spasmolytic effects. *Chin J Integr Med* 2012; In Press.
 - 35 **Smith GD**. Review paper: The use of aloe vera in ulcerative colitis. *Gastrointestinal Nursing* 2012; 10(6): 11-12.